International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 5 , Pages 1145-1153 , 1 August 2001

Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy

Presented at the 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, Massachusetts, October 22–26, 2000.

  • Arno J Mundt, M.D.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, IL, USA
    • Corresponding Author InformationReprint requests to: Arno J. Mundt, M.D., Department of Radiation and Cellular Oncology, University of Chicago Hospitals, MC 9006, 5758 S. Maryland Ave, Chicago, IL 60637. Tel: (773) 702-4751; Fax: (773) 702-0610
    • ,
  • Russell McBride, B.A.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, IL, USA
    • ,
  • Jacob Rotmensch, M.D.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, IL, USA
    • Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Hospitals, Chicago, IL, USA
    • ,
  • Steven E Waggoner, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Hospitals, Chicago, IL, USA
    • ,
  • S.Diane Yamada, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Hospitals, Chicago, IL, USA
    • ,
  • Philip P Connell, M.D.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, IL, USA

,Accepted 14 March 2001.

References 

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. CA Cancer J Clin. 1998;48:6–29
  2. In:  Petterseon F editors. Annual report on the results of treatment in gynecologic cancer. Vol 22, Stockholm. International Federation of Gynecology and Obstetrics; 1994;p. 72–92
  3. Greven KM, Curran WJ, Whittington R, et al.  Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. Int J Radiat Oncol Biol Phys. 1989;17:35–39
  4. Kadar N, Homesley HD, Malfetano JH. Prognostic factors in surgical stage III and IV carcinoma of the endometrium. Obstet Gynecol. 1994;84:983–986
  5. Dunton J, Balsara G, McFarland M, et al.  Uterine papillary serous carcinoma (A review). Obstet Gynecol Surv. 1997;46:97–102
  6. Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium (A histopathological study of 22 cases). Gynecol Oncol. 1990;39:266–271
  7. Potish RA, Twiggs LB, Adcock LL, et al.  Role of whole abdominal radiation therapy in the management of endometrial cancer (Prognostic importance of factors indicating peritoneal metastases). Gynecol Oncol. 1985;21:80–86
  8. Gibbons S, Martinez A, Schray M. Adjuvant whole abdominopelvic irradiation for high-risk endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1991;21:1019–1025
  9. Burke TW, Gershenson DM. Chemotherapy as adjuvant and salvage treatment in women with endometrial carcinoma. Clin Obstet Gynecol. 1996;39:716–727
  10. Pustilnik T, Burke TW. Adjuvant chemotherapy for high-risk endometrial cancer. Semin Radiat Oncol. 2000;10:23–28
  11. Thigpen JT, Blessing JA, DiSaia PJ, et al.  A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma (A Gynecol Oncol Group study). J Clin Oncol. 1994;12:1408–1414
  12. Burke TW, Stringer CA, Morris M, et al.  Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol. 1991;40:264–267
  13. Alberts DS, Masson NL, O’Toole RV, et al.  Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma (A Southwest Oncology Group study). Gynecol Oncol. 1987;26:193–200
  14. Levenback C, Burke TW, Silva E, et al.  Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol. 1992;46:317–321
  15. Smith MR, Peters WA, Drescher CW. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am J Obstet Gynecol. 1994;170:1677–1681
  16. Morrow CP, Bundy BN, Homesley HD, et al.  Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II (A Gynecol Oncol Group Study). Gynecol Oncol. 1990;36:166–171
  17. O’Brien ME, Killackey M. Adjuvant therapy in high risk endometrial adenocarcinoma. Proc Ann Meet Am Soc Clin Oncol. 1994;13:249;(Abstr)
  18. Jennings S, Dotiino P, Johnston C, et al.  Adjuvant cisplatin, doxorubicin, and etoposide and pelvic radiotherapy for advanced stage or virulent histologic subtypes of endometrial cancer. Proc Ann Meet Am Soc Clin Oncol. 1993;12:268;(Abstr)
  19. Frigero LL, Mangeli GG, Aletti GG, et al.  Concomitant radiotherapy and paclitaxel for high-risk endometrial carcinoma (First feasibility study). (Abstr.) Gynecol Oncol. 2000;76:249
  20. Rosenberg P, Boeryd B, Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol. 1993;48:32–37
  21. Fung MF, Krepart GV, Lotocki RJ, et al.  Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxyprogesterone acetate. Obstet Gynecol. 1991;78:1033–1038
  22. Turner BC, Knisely JP, Kacinski BM, et al.  Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. Int J Radiat Oncol Biol Phys. 1998;40:77–84
  23. Stringer CA, Gershenson DM, Burke TW, et al.  Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer (A preliminary analysis). Gynecol Oncol. 1990;38:305–308
  24. Burke TW, Gershenson DM, Morris M, et al.  Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994;55:47–50
  25. Price FV, Chambers SK, Carcangiu ML, et al.  Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 1993;51:383–389
  26. Tsunoda H, Nishida M, Arisawa Y, et al.  Adjuvant chemotherapy with cyclophosphamide, adriamycin, and CDDP (CAP) for high risk endometrial cancer after complete surgery. Nippon Sanka Fujinka Gakkai Zasshi. 1996;48:45–51
  27. Fujimura H, Kikkawa F, Oguchi H, et al.  Adjuvant chemotherapy including cisplatin in endometrial carcinoma. Gynecol Oncol Invest. 2000;50:127–132
  28. Randall ME, Spirtos NM, Dvoretsky P. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III) (Gynecol Oncol Group Study No. 122). Monogr Natl Cancer Inst. 1995;19:13–15
  29. Greven KM. Tailoring radiation to the extent of disease for uterine-confined endometrial cancer. Semin Radiat Oncol. 2000;10:29–35
  30. Roberts JA, Brunetto VL, Keys HM, et al.  A phase III randomized trial of surgery vs. surgery plus adjunctive radiation therapy in intermediate risk endometrial adenocarcinoma (GOG 99). Proc Soc Gynecol Oncol. 1998;29:70;(Abstr)
  31. Weiss MF, Connell PP, Waggoner S, et al.  External pelvic radiation therapy in stage IC endometrial carcinoma. Obstet Gynecol. 1999;93:599–602
  32. Creutzberg CL, van Putten WL, Koper PC, et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage I endometrial carcinoma (Multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma). Lancet. 2000;355:1404–1411
  33. International Federation of Gynecology and Obstetrics . Annual report of the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 1988;20:75–77
  34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  35. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  36. Overgaard M, Jensen MB, Overgaard J, et al.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen (Danish Breast Cancer Cooperative Group DBCG 82c randomised trial). Lancet. 1999;353:1641–1648
  37. Ragaz J, Jackson SM, Le N, et al.  Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–962
  38. Marks LB, Halperin EC, Prosnitz LR, et al.  Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. Int J Radiat Oncol Biol Phys. 1992;23:1021–1026
  39. Jabro G, Wazer DE, Rithazer R, et al.  The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with >/= 10 positive axillary nodes. Int J Radiat Oncol Biol Phys. 1999;44:273–280
  40. Wolmark N, Wieand HS, Hyams DM, et al.  Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum (National Surgical Adjuvant Breast and Bowel Project Protocol R-02). J Natl Cancer Inst. 2000;92:388–396
  41. Aalders J, Abeler V, Kolstad P, et al.  Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma (Clinical and histopathologic study of 540 patients). Obstet Gynecol. 1980;56:419–427
  42. Zaino RJ, Kurman RJ, Diana KL, et al.  Pathologic models to predict outcome for women with endometrial adenocarcinoma (The importance of the distinction between surgical stage and clinical stage-a Gynecol Oncol Group study). Cancer. 1996;77:1115–1121
  43. Algan O, Tabesh T, Hanlon A, et al.  Improved outcome in patients treated with postoperative radiation therapy for pathologic stage I/II endometrial cancer. Int J Radiat Oncol Biol Phys. 1998;35:925–933
  44. Calvin DP, Connell PP, Rotmensch J, et al.  Surgery and postoperative radiation therapy in stage II endometrial carcinoma. Am J Clin Oncol. 1999;22:338–343
  45. Greven KM, Lanciano RM, Corn B, et al.  Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer. 1993;71:3697–3702
  46. Creasman WT, Morrow CP, Bundy BN, et al.  Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60:2035–2041
  47. Nelson G, Randall M, Sutton G, et al.  FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes (Analysis of treatment outcomes, prognostic variables and failure patterns following adjuvant radiation therapy). Gynecol Oncol. 1999;75:211–214
  48. Murphy K, Connell PP, McBride R, et al.  FIGO stage IIIC endometrial cancer patients undergoing surgery and adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48:123;(Abstr.)
  49. Roeske JC, Lujan A, Rotmensch J, et al.  Intensity modulated whole pelvic radiation therapy in patients with gynecological malignancies. Int J Radiat Oncol Biol Phys. 2000;48:1613–1621
  50. Mundt AJ, Roeske JC, Lujan A, et al. Initial clinical experience with intensity modulated whole pelvic radiation therapy in women with gynecologic malignancies. Gynecol Oncol (in press).
  51. Portelance L, Chao C, Grigsby PW, et al.  Intensity modulated radiation therapy (IMRT) may reduce small bowel, rectum and bladder complications in patients with cervical cancer treated to the pelvis and paraortics area. Int J Radiat Oncol Biol Phys. 1999;45(Suppl. 1):211;(Abstr.)

PII: S0360-3016(01)01566-8

International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 5 , Pages 1145-1153 , 1 August 2001

Article Tools

* Image Usage & Resolution